Prostaglandin E1 vasospastic disease and thermography
- PMID: 3977414
- PMCID: PMC1001576
- DOI: 10.1136/ard.44.2.73
Prostaglandin E1 vasospastic disease and thermography
Abstract
This is the first study to show a quantitative thermographic difference between patients with Raynaud's syndrome and normal controls after cold stress testing. An improved thermographic response to cold stress testing after treatment of Raynaud's syndrome with PGE1 has also been shown for the first time. Discriminant analysis of the change in temperature of a finger after cold stress, and the mean thermal gradient along the finger during rewarming, clearly separated patients from controls. After treatment with PGE1 the patients' discriminant values moved into the normal range. Symptomatic improvement after PGE1 correlated well with thermographic improvement, and both persisted for up to 12 weeks.
Similar articles
-
Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.Ann Rheum Dis. 1981 Aug;40(4):350-4. doi: 10.1136/ard.40.4.350. Ann Rheum Dis. 1981. PMID: 7259326 Free PMC article. Clinical Trial.
-
Pyroelectric vidicon thermography and cold challenge quantify the severity of Raynaud's phenomenon.Br J Rheumatol. 1991 Jun;30(3):190-5. doi: 10.1093/rheumatology/30.3.190. Br J Rheumatol. 1991. PMID: 2049579
-
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.Rheumatology (Oxford). 2001 Sep;40(9):1038-43. doi: 10.1093/rheumatology/40.9.1038. Rheumatology (Oxford). 2001. PMID: 11561116 Clinical Trial.
-
Use of prostaglandin E1 (lipo-PGE1) to treat Raynaud's phenomenon associated with connective tissue disease: thermographic and subjective assessment.J Pharm Pharmacol. 1992 May;44(5):442-4. doi: 10.1111/j.2042-7158.1992.tb03641.x. J Pharm Pharmacol. 1992. PMID: 1359062 Clinical Trial.
-
The carpal tunnel syndrome--a disease underlying Raynaud's phenomenon?Angiology. 1988 Oct;39(10):891-901. doi: 10.1177/000331978803901006. Angiology. 1988. PMID: 3052182 Review.
Cited by
-
Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin.Br J Clin Pharmacol. 1991 Aug;32(2):209-13. doi: 10.1111/j.1365-2125.1991.tb03883.x. Br J Clin Pharmacol. 1991. PMID: 1931469 Free PMC article. Clinical Trial.
-
Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis.Ann Rheum Dis. 1998 Feb;57(2):70-8. doi: 10.1136/ard.57.2.70. Ann Rheum Dis. 1998. PMID: 9613334 Free PMC article. Review. No abstract available.
-
Managing Raynaud's phenomenon.Br Med J (Clin Res Ed). 1986 Jul 12;293(6539):88-9. doi: 10.1136/bmj.293.6539.88. Br Med J (Clin Res Ed). 1986. PMID: 3089429 Free PMC article. No abstract available.
-
A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.Ann Rheum Dis. 1991 Nov;50(11):800-4. doi: 10.1136/ard.50.11.800. Ann Rheum Dis. 1991. PMID: 1722967 Free PMC article. Clinical Trial.
-
Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.Ann Rheum Dis. 1988 Jan;47(1):43-7. doi: 10.1136/ard.47.1.43. Ann Rheum Dis. 1988. PMID: 2449871 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical